Tools / Drugs Amoxicillin; Clavulanate potassium Treats infections due to susceptible isolates of the designated bacteria in the…. Sold as Augmentin '250', Augmentin '500', Augmentin '125', Augmentin '875', Augmentin '200' and 3 more. Every FDA application for this active ingredient: 8 branded and 41 generic.
As of Nov 22, 2026, FDA lists 49 applications for Amoxicillin; Clavulanate potassium (sold as Augmentin '250', Augmentin '500', Augmentin '125' and others), first approved Aug 6, 1984, with 3 new uses approved and 0 published complete response letters.
Applications : 49 New uses approved : 3 Complete response letters : 0 Mechanism of action and target, from ChEMBL Uses, approved and in trials Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Soft tissue infections Approved NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Aug 6, 1984 Augmentin '250', Augmentin '500' NDA 50564 · New molecular entity, new combination US Antibiotics48 Discontinued Aug 6, 1984 Augmentin '125', Augmentin '250' NDA 50575 · New dosage form US Antibiotics31 Marketed Jul 22, 1985 Augmentin '125', Augmentin '250' NDA 50597 · New dosage form US Antibiotics47 Discontinued Feb 13, 1996 Augmentin '875' NDA 50720 · New dosage form US Antibiotics29 Marketed May 31, 1996 Augmentin '200', Augmentin '400' NDA 50725 · New dosage form US Antibiotics32 Discontinued May 31, 1996 Augmentin '200', Augmentin '400' NDA 50726 · New dosage form US Antibiotics24 Discontinued Jun 22, 2001 Augmentin ES-600 NDA 50755 · New dosage form US Antibiotics19 Marketed Mar 14, 2002 Amoxicillin and Clavulanate Potassium ANDA 65063 Sandoz13 Marketed Mar 15, 2002 Amoxicillin and Clavulanate Potassium ANDA 65064 Sandoz13 Marketed Apr 18, 2002 Amoxicillin and Clavulanate Potassium ANDA 65065 Chartwell RX15 Discontinued Jun 5, 2002 Amoxicillin and Clavulanate Potassium ANDA 65066 Sandoz11 Marketed Sep 17, 2002 Amoxicillin and Clavulanate Potassium ANDA 65102 Sun Pharmaceutical Industries6 Discontinued Sep 25, 2002 Augmentin XR NDA 50785 · New dosage form US Antibiotics17 Marketed Oct 29, 2002 Amoxicillin and Clavulanate Potassium ANDA 65096 Chartwell RX14 Marketed Oct 30, 2002 Amoxicillin and Clavulanate Potassium ANDA 65101 Chartwell RX12 Marketed Nov 4, 2002 Amoxicillin and Clavulanate Potassium ANDA 65109 Sun Pharmaceutical Industries6 Discontinued Nov 21, 2002 Amoxicillin and Clavulanate Potassium ANDA 65093 Sandoz8 Marketed Nov 27, 2002 Amoxicillin and Clavulanate Potassium ANDA 65117 Sandoz8 Discontinued Dec 16, 2002 Amoxicillin and Clavulanate Potassium ANDA 65098 Sandoz5 Marketed Mar 19, 2003 Amoxicillin and Clavulanate Potassium ANDA 65132 Sun Pharmaceutical Industries4 Discontinued Dec 3, 2003 Amoxicillin and Clavulanate Potassium ANDA 65161 Sun Pharmaceutical Industries3 Discontinued Mar 12, 2004 Amoxicillin and Clavulanate Potassium ANDA 65162 Chartwell RX9 Marketed May 25, 2004 Amoxicillin and Clavulanate Potassium ANDA 65089 Chartwell RX7 Marketed Jan 25, 2005 Amoxicillin and Clavulanate Potassium ANDA 65191 Hikma Pharmaceuticals7 Marketed Feb 9, 2005 Amoxicillin and Clavulanate Potassium ANDA 65205 Chartwell RX10 Marketed Aug 23, 2005 Amoxicillin and Clavulanate Potassium ANDA 65189 Sandoz7 Marketed Jan 30, 2007 Amoxicillin and Clavulanate Potassium ANDA 65207 Sun Pharmaceutical Industries0 Discontinued Aug 13, 2007 Amoxicillin and Clavulanate Potassium ANDA 65358 Sandoz6 Marketed Nov 9, 2007 Amoxicillin and Clavulanate Potassium ANDA 65373 Hikma Pharmaceuticals8 Marketed Oct 20, 2008 Amoxicillin and Clavulanate Potassium ANDA 65317 Apotex5 Discontinued Nov 25, 2008 Amoxicillin and Clavulanate Potassium ANDA 65431 Cipla1 Marketed Feb 24, 2009 Amoxicillin and Clavulanate Potassium ANDA 65333 Apotex5 Discontinued Apr 21, 2010 Amoxicillin and Clavulanate Potassium ANDA 90227 Sandoz5 Marketed Dec 20, 2011 Amoxicillin and Clavulanate Potassium ANDA 201090 Aurobindo Pharma5 Marketed Dec 20, 2011 Amoxicillin and Clavulanate Potassium ANDA 201091 Aurobindo Pharma4 Marketed Jan 20, 2012 Amoxicillin and Clavulanate Potassium ANDA 91568 Aurobindo Pharma6 Marketed Jan 20, 2012 Amoxicillin and Clavulanate Potassium ANDA 91569 Aurobindo Pharma6 Marketed Dec 2, 2013 Amoxicillin and Clavulanate Potassium ANDA 65420 Cipla1 Marketed Aug 23, 2016 Amoxicillin and Clavulanate Potassium ANDA 203824 Hikma Pharmaceuticals2 Marketed Dec 30, 2016 Amoxicillin and Clavulanate Potassium ANDA 205707 Micro Labs Ltd India6 Marketed Dec 30, 2016 Amoxicillin and Clavulanate Potassium ANDA 204755 Micro Labs Ltd India6 Marketed Apr 19, 2019 Amoxicillin and Clavulanate Potassium ANDA 209371 Aurobindo Pharma3 Marketed May 21, 2021 Amoxicillin and Clavulanate Potassium ANDA 205187 Micro Labs Ltd India2 Discontinued Sep 13, 2023 Amoxicillin and Clavulanate Potassium ANDA 209351 Deva Holding A.S.0 Marketed Sep 15, 2023 Amoxicillin and Clavulanate Potassium ANDA 209991 Regcon Holdings0 Marketed Sep 15, 2023 Amoxicillin and Clavulanate Potassium ANDA 209992 Regcon Holdings0 Marketed Nov 29, 2023 Amoxicillin and Clavulanate Potassium ANDA 210374 Deva Holding A.S.0 Marketed Dec 8, 2023 Amoxicillin and Clavulanate Potassium ANDA 217805 Micro Labs2 Discontinued Dec 11, 2023 Amoxicillin and Clavulanate Potassium ANDA 210416 Deva Holding A.S.0 Marketed
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Amoxicillin $178.3M for 15,280,637 prescriptions, −9% on 2024 How its trials ended 14 ClinicalTrials.gov studies testing it, classified by TrialPanorama , partly automatically, so some labels are wrong Of the 5 whose ending is known, 80% met their primary endpoint, 0% missed it and 20% stopped early.
Completed, result not reported 5 36%Completed, result not reported Count5 Share36% Met its primary endpoint 4 29%Met its primary endpoint Count4 Share29% Status unknown 3 21%Status unknown Count3 Share21% Ongoing 1 7%Ongoing Count1 Share7% Stopped: other or unclear 1 7%Stopped: other or unclear Count1 Share7% Approvals in Canada (Health Canada) New drug submissions since 1994, matched by ingredient; see all Canadian approvals Alti-Amoxi Clav Altimed Pharma Inc., Division of Technilab Pharma Inc. · Apr 9, 2001 PMS-Amclav Pharmascience Inc. · Oct 31, 1995 35 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Antibiotic Tissue Penetration and Tissue Response in Head and Neck Infection and Reconstructive Surgery Surgical Wound Infection, Neck Infection · Tejs Ehlers Klug Phase 4 Recruiting Oct 26, 2026 Amoxicillin-clavulanate Versus Amoxicillin Versus Placebo in Acute Otitis Media in Children Acute Otitis Media, AOM - Acute Otitis Media · Kuopio University Hospital Phase 4 Not yet recruiting Oct 16, 2026 Patient Choice Between Antibiotics and Appendectomy in Uncomplicated Appendicitis (FRENCH 47 - ALACARTE) Acute Appendicitis · Assistance Publique - Hôpitaux de Paris Phase 2 Not yet recruiting Oct 5, 2026 Effectiveness of Saccharomyces Boulardii in Prevention of Antibiotic Associated Diarrhea Antibiotic Associated Diarrhea, Upper Respiratory Tract Infection · University of Child Health Sciences and Children's Hospital, Lahore Not applicable Not yet recruiting Aug 25, 2026 Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Liver Transplant, Carbapenem-resistant Enterobacterales · IRCCS Azienda Ospedaliero-Universitaria di Bologna Phase 3 Not yet recruiting Aug 12, 2026 Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery Impacted Mandibular Third Molar Extraction, Impacted Lower Third Molar · Final International University Not applicable Recruiting Aug 3, 2026 Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis) ACUTE SINUSITIS, Sinusitis · Nader Shaikh Phase 4 Recruiting Jul 29, 2026 Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media) Acute Otitis Media (AOM) · Nader Shaikh Phase 4 Recruiting Jul 28, 2026
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA